Almost no increase in IP-10 concentrations above those induced by IFN-γ was seen in HNSCC samples treated with pembrolizumab plus IFN-γ, as an increased IP-10 release was registered only in 6 out of 23 HNSCC samples. This evidence concerns the gene IFNG and head and neck squamous cell carcinoma.